The selected 112 genes were chosen based on the following criteria: (a) commonly found in myeloma patients tested with our institute’s conventional NGS panel (742 genes), (b) involved in important signaling pathways in multiple myeloma e.g. the MAPK, MYC, DNA repair and NFKB pathways, and (c) treatment targets or candidates for drug resistance in multiple myeloma (e.g. IKZF3, BCL2, PTEN and NFKB2) [19–22]. This evidence concerns the gene BCL2 and AL amyloidosis.